Revenue
1 thousand USD
2027 Q1 · USD
Exact inputs and evidence
- Revenue: 1000 USD Source
Fundies. English
MEDICAL EXERCISE INC.
EDGARAnnual consolidated revenue for 2025: about USD 1.294K, using the latest reported figures.
Holdings and insider activity
Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, over the last 12 months.
Insider filings have not been processed for this company yet.
Short annual reporting periods
These figures cover less than a full year. They are not annualized and are excluded from full-year trends and comparisons.
Reported figures
| Measure | Period | Value |
|---|---|---|
| Capital expenditure | 2023-09-21 – 2024-03-31 | 14255 USD Source Dispute |
| Cost of revenue | 2023-09-21 – 2024-03-31 | 830 USD Source Dispute |
| Gross profit | 2023-09-21 – 2024-03-31 | 1975 USD Source Dispute |
| Net income | 2023-09-21 – 2024-03-31 | -148014 USD Source Dispute |
| Operating cash flow | 2023-09-21 – 2024-03-31 | -70081 USD Source Dispute |
| Operating expenses | 2023-09-21 – 2024-03-31 | 149989 USD Source Dispute |
| Operating income | 2023-09-21 – 2024-03-31 | 1975 USD Source Dispute |
| Revenue | 2023-09-21 – 2024-03-31 | 2805 USD Source Dispute |
| Selling, general and administrative | 2023-09-21 – 2024-03-31 | 50794 USD Source Dispute |
Latest quarter
- Cash and cash equivalents
- 3.09 thousand USD Source
Exact value
3089 USD
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 13.3 million shares Source
Exact value
13327000 shares
Reported share-count change
8.11% · 1 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Net income
-209 thousand USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
Operating cash flow
-163 thousand USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
- Operating cash flow: -100424 USD · 2025-04-01 – 2025-09-30 Source
- Operating cash flow: -78583 USD · 2025-04-01 – 2025-06-30 Source
- Operating cash flow: -177215 USD · 2025-04-01 – 2025-12-31 Source
- Operating cash flow: -100424 USD · 2025-04-01 – 2025-09-30 Source
- Operating cash flow: -194751 USD · 2025-04-01 – 2026-03-31 Source
- Operating cash flow: -177215 USD · 2025-04-01 – 2025-12-31 Source
- Operating cash flow: -46722 USD · 2026-04-01 – 2026-06-30 Source
Capital expenditure
3.87 thousand USD
2024-04-01 – 2025-03-31
Exact inputs and evidence
- Capital expenditure: 3869 USD · 2024-04-01 – 2024-06-30 Source
- Capital expenditure: 3869 USD · 2024-04-01 – 2024-09-30 Source
- Capital expenditure: 3869 USD · 2024-04-01 – 2024-06-30 Source
- Capital expenditure: 3869 USD · 2024-04-01 – 2024-12-31 Source
- Capital expenditure: 3869 USD · 2024-04-01 – 2024-09-30 Source
- Capital expenditure: 3869 USD · 2024-04-01 – 2025-03-31 Source
- Capital expenditure: 3869 USD · 2024-04-01 – 2024-12-31 Source
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-08-19.
Financial data available through: 2025-03-31.
Financial coverage is incomplete. Newer filings are recorded, but comparable financial figures for those periods are not available here yet.
Coverage by financial measure
- Revenue: 1 of 11 periods available· newest 2025-03-31
- Operating income: 1 of 11 periods available· newest 2025-03-31
- Net income: 1 of 11 periods available· newest 2025-03-31
- Operating cash flow: 1 of 11 periods available· newest 2025-03-31
- Capital expenditure: 1 of 11 periods available· newest 2025-03-31
- Total assets: 1 of 11 periods available· newest 2025-03-31
- liabilities: No compatible figures in this window
- Current assets: 1 of 11 periods available· newest 2025-03-31
- Current liabilities: 1 of 11 periods available· newest 2025-03-31
- Cash and cash equivalents: 1 of 11 periods available· newest 2025-03-31
- long term debt: No compatible figures in this window
- Shares outstanding: 1 of 11 periods available· newest 2025-03-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
No unambiguous prior-year comparison is available for the latest reporting period.
Comparable inputs unavailable for: Revenue, Net income, Operating cash flow, Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
2025 2024-04-01 – 2025-03-31
- Revenue USD 1,294 100% of revenue
- Cost of revenue USD 445 34% of revenue
- Operating expenses USD 332,223 25,674% of revenue
- Operating income −USD 331,374 −25,609% of revenue
- Tax, interest and other Derived −USD 389 −30% of revenue
- Net income −USD 330,985 −25,578% of revenue
Cash
- Operating cash flow −USD 191,027 −14,763% of revenue
- Capital expenditure USD 3,869 299% of revenue
- Free cash flow Derived −USD 194,896 −15,062% of revenue
Share of revenue by period
- Net income
- Tax, interest and other
- Operating costs
- 2025 Operating loss: operating costs were 25,709% of revenue.
Values and sources
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2025 2024-04-01 – 2025-03-31 | 1294 | 332668 Derived | -331374 | -389 Derived | -330985 | -194896 Derived | Source
|
Amounts are exact, in USD.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
USD 1.3K 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2025 | Revenue | 1294 |
|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2025 | Year over year | No prior comparable period |
|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Operating margin -25,608.5% 2025
Net margin -25,578.4% 2025
Free cash flow margin -15,061.5% 2025
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2025 | Operating margin | -25,608.5% |
|
| 2025 | Net margin | -25,578.4% |
|
| 2025 | Free cash flow margin | -15,061.5% |
|
Operating cash flow
Cash generated by the company’s normal business operations.
USD -191K 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2025 | Operating cash flow | -191027 |
|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
USD -194.9K 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2025 | Free cash flow | -194896 |
|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2025-03-31 | Liabilities / assets | Not reported |
|
Current assets to current liabilities
Current assets divided by current liabilities.
0× 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2025 | Current assets / current liabilities | 0× |
|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2025 2024-04-01 – 2025-03-31 | −USD 330,985 Exact valueExact value: -330985 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 191,027 Exact valueExact value: -191027 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 3,869 Exact valueExact value: 3869 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 194,896 Calculation and evidence-191027 − 3869 USD Exact free cash flow: -194896 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
7 filings · 409 latest values · 409 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0002001249, 2001249, edgar:2001249
Also known as MEDICAL EXERCISE INC., MEDX BACK PAIN CLINICS INC.